Hackensack University Medical Center

Running trials

• Not yet recruiting

  Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

  NCT06708455· Phase 2· Rapa Therapeutics LLC· Source

• Recruiting

  INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

  NCT06965504· Abiomed Inc.· Source

• Not yet recruiting

  A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

  NCT06458907· P+F Products + Features USA Inc.· Source

• Recruiting

  WATER IV PCa (AS Sub-study)

  NCT07650448· PROCEPT BioRobotics· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  NCT07215910· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

  NCT07488923· Phase 1· Moonlight Bio, Inc· Source

• Recruiting

  A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

  NCT07629960· Phase 1/2· Blueprint Medicines Corporation· Source

• Recruiting

  Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

  NCT06980038· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

  NCT06465199· Phase 1/2· Milton S. Hershey Medical Center· Source

• Recruiting

  A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

  NCT07488676· Phase 1/2· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

  NCT07068074· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  A Gaucher Disease Gene Therapy Trial With FLT201

  NCT07223944· Phase 3· Spur Therapeutics· Source

• Recruiting

  Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

  NCT07227298· Phase 1/2· Pfizer· Source

• Recruiting

  Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  NCT07444814· Phase 1· Whitehawk Therapeutics, Inc.· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

  NCT07285460· Phase 3· Sanofi· Source

• Recruiting

  Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

  NCT06323447· Leuko Labs, Inc.· Source

• Recruiting

  A Long-term Follow-up Study in Patients Who Received BEAM-101

  NCT07373639· Beam Therapeutics Inc.· Source

• Active, not recruiting

  A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07023627· Phase 2· Incyte Corporation· Source

• Recruiting

  CCM OPEN HF Registry

  NCT07112924· Impulse Dynamics· Source

• Recruiting

  A Study of ZW251 in Participants With Advanced Solid Tumors

  NCT07164313· Phase 1· Zymeworks BC Inc.· Source

• Recruiting

  A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06988488· Phase 1/2· Celgene· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· Phase 3· BeOne Medicines· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Active, not recruiting

  Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

  NCT07021066· Phase 1· SystImmune Inc.· Source

• Recruiting

  A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

  NCT07094204· Phase 1· Astellas Pharma Inc· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

  NCT07000084· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

  NCT07075185· Phase 1· Kelonia Therapeutics, Inc.· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

  NCT06658730· W.L.Gore & Associates· Source

• Recruiting

  Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  NCT06317662· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

  NCT06544330· Phase 1· Synthekine· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  NCT06818812· Phase 1· Incyte Corporation· Source

• Active, not recruiting

  A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06356571· Phase 2· Sanofi· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

  NCT06869785· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Embryonal Tumor With Multilayered Rosettes

  NCT06861244· Phase 2· University of California, San Francisco· Source

• Recruiting

  A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  NCT06778863· Phase 1· Clasp Therapeutics, Inc.· Source

• Recruiting

  Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

  NCT06513962· Phase 3· Children's Oncology Group· Source

• Recruiting

  A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

  NCT06792552· Phase 1· NextCure, Inc.· Source

• Recruiting

  Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  NCT06632977· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  WATER IV Prostate Cancer

  NCT06651632· PROCEPT BioRobotics· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Recruiting

  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

  NCT06747585· Phase 1/2· Alentis Therapeutics AG· Source

• Recruiting

  Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

  NCT06526195· Abbott Medical Devices· Source

• Recruiting

  AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

  NCT06699056· Peerbridge Health, Inc· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

Showing 50 of 265.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers38 recruiting
• Lung cancer15 recruiting
• Acute lymphoblastic leukaemia9 recruiting
• Heart failure9 recruiting
• Multiple myeloma8 recruiting
• Ovarian cancer8 recruiting
• Sarcoma8 recruiting
• Acute myeloid leukaemia5 recruiting
• Colorectal cancer5 recruiting
• Pancreatic cancer5 recruiting
• Prostate cancer5 recruiting
• Bladder cancer4 recruiting
• Head and neck cancer4 recruiting
• Kidney cancer4 recruiting
• Melanoma4 recruiting
• Neuroblastoma4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Down syndrome3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Atrial fibrillation2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Hodgkin lymphoma2 recruiting
• Liver and biliary tract cancer2 recruiting
• Lupus (SLE)2 recruiting
• Neuroendocrine tumours2 recruiting
• Sickle cell disease2 recruiting
• Stroke2 recruiting
• Triple-negative breast cancer2 recruiting
• Amyloidosis1 recruiting
• Aortic aneurysm1 recruiting
• Aplastic anaemia1 recruiting
• Coronary artery disease1 recruiting
• Dilated cardiomyopathy1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• Gaucher disease1 recruiting
• Haemophilia1 recruiting
• High blood pressure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• IgA nephropathy1 recruiting
• Metastatic breast cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Pompe disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting

Closed trials

• Withdrawn

  Ceftriaxone for Post-Treatment Lyme Disease

  NCT06785402· Phase 1/2· Hackensack Meridian Health· Source

• Recruiting

  A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

  NCT07140016· Phase 1· Astellas Pharma Global Development, Inc.· Source

• Completed

  Speech-derived Digital Biomarkers Study

  NCT06994767· Hackensack Meridian Health· Source

• Terminated

  A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

  NCT05983133· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  NCT05894239· Phase 3· Hoffmann-La Roche· Source

• Terminated

  Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

  NCT05580588· Phase 2· Shanghai Pharma Biotherapeutics USA Inc.· Source

• Terminated

  Tack Optimized Balloon Angioplasty Post-Market Study

  NCT05361967· Spectranetics Corporation· Source

• Withdrawn

  INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT05359692· Phase 2· Incyte Biosciences International Sàrl· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Terminated

  A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

  NCT05600426· Phase 3· Boston Children's Hospital· Source

• Terminated

  A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

  NCT05514717· Phase 1· Day One Biopharmaceuticals, Inc.· Source

• Completed

  Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT05287113· Phase 2· Incyte Biosciences International Sàrl· Source

• Withdrawn

  A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

  NCT05572463· Phase 1/2· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Completed

  Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

  NCT05479812· Phase 1· Werewolf Therapeutics, Inc.· Source

• Completed

  Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

  NCT05405114· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

  NCT05347485· Phase 2· Janssen Scientific Affairs, LLC· Source

• Terminated

  Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

  NCT05289492· Phase 1· iTeos Therapeutics· Source

• Terminated

  Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

  NCT05305040· Phase 2/3· AlloVir· Source

• Completed

  Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation

  NCT04950894· LivaNova· Source

• Terminated

  A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

  NCT05181540· Phase 3· Angiocrine Bioscience· Source

• Recruiting

  Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

  NCT04628767· Phase 2/3· National Cancer Institute (NCI)· Source

• Terminated

  Study of INCA 0186 in Subjects With Advanced Solid Tumors

  NCT04989387· Phase 1· Incyte Corporation· Source

• Terminated

  A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma

  NCT04996004· Phase 2· Pfizer· Source

• Completed

  Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

  NCT04880434· Phase 2· Kite, A Gilead Company· Source

• Terminated

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

  NCT04272034· Phase 1· Incyte Corporation· Source

• Completed

  MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

  NCT04649359· Phase 2· Pfizer· Source

• Terminated

  A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

  NCT04543188· Phase 1· Pfizer· Source

• Completed

  A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

  NCT04620330· Phase 2· Verastem, Inc.· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

  NCT04539938· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Terminated

  A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

  NCT04432207· Phase 1· Imugene Limited· Source

• Completed

  LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

  NCT04577807· Phase 2· Istari Oncology, Inc.· Source

• Completed

  A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

  NCT04309474· Phase 2· AbbVie· Source

• Completed

  Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

  NCT04472598· Phase 3· AbbVie· Source

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Phase 1· Pfizer· Source

• Completed

  SURPASS Impella 5.5 Study

  NCT05100836· Abiomed Inc.· Source

• Completed

  Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

  NCT04295538· Phase 2· AbbVie· Source

• Completed

  Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

  NCT04396860· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

  NCT04377555· Phase 4· Genentech, Inc.· Source

• Completed

  Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

  NCT04370704· Phase 1/2· Incyte Corporation· Source

• Terminated

  MMRF CureCloud Research Initiative

  NCT03657251· Multiple Myeloma Research Foundation· Source

• Terminated

  Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  NCT04231747· Phase 1· Juno Therapeutics, a Subsidiary of Celgene· Source

• Completed

  Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

  NCT03974113· Phase 2/3· Genzyme, a Sanofi Company· Source

• Completed

  A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

  NCT04138277· Phase 3· Amicus Therapeutics· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  NCT04065399· Phase 1/2· Syndax Pharmaceuticals· Source

• Terminated

  Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

  NCT04059484· Phase 2· Sanofi· Source

• Recruiting

  A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  NCT04104776· Phase 1/2· Novartis Pharmaceuticals· Source

• Completed

  An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

  NCT03915951· Phase 2· Pfizer· Source

Showing 50 of 131.

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple myeloma23 works · 34 trials
• Hodgkin lymphoma10 works · 11 trials
• Mantle cell lymphoma7 works · 2 trials